At present, PSMA-PET is routinely used for the staging of patients with newly diagnosed intermediate to high-risk prostate cancer, patients with biochemically recurrent prostate cancer, or to assess eligibility of PSMA RLT (radioligand therapy) in castration resistant prostate cancer 14,15. This evidence concerns the gene FOLH1 and Familial prostate cancer.